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Abstract
Background: Previous studies demonstrated that lower outdoor temperatures increase the levels of established car-
diovascular disease risk factors, such as blood pressure and lipids. Whether or not low temperatures increase novel
cardiovascular disease risk factors levels is not well studied. The aim was to investigate associations of outdoor tem-
perature with a comprehensive range of established and novel cardiovascular disease risk factors in two large Northern
European studies of older adults, in whom cardiovascular disease risk is increased.
Design and methods: Data came from the British Regional Heart Study (4252 men aged 60–79 years) and the
Prospective Study of Pravastatin in the Elderly at Risk (5804 men and women aged 70–82 years). Associations between
outdoor temperature and cardiovascular disease risk factors were quantified in each study and then pooled using a
random effects model.
Results: With a 5C lower mean temperature, total cholesterol was 0.04 mmol/l (95% confidence interval (CI) 0.02–0.07)
higher, low density lipoprotein cholesterol was 0.02 mmol/l (95% CI 0.01–0.05) higher and SBP was 1.12 mm Hg (95% CI
0.60–1.64) higher. Among novel cardiovascular disease risk factors, C-reactive protein was 3.3% (95% CI 1.0–5.6%) higher,
interleukin-6 was 2.7% (95% CI 1.1–4.3%) higher, and vitamin D was 11.2% (95% CI 1.0–20.4%) lower.
Conclusions: Lower outdoor temperature was associated with adverse effects on cholesterol, blood pressure, circu-
lating inflammatory markers, and vitamin D in two older populations. Public health approaches to protect the elderly
against low temperatures could help in reducing the levels of several cardiovascular disease risk factors.
Keywords
Biomarkers, outdoor temperature, older adults, cardiovascular disease risk factors
Received 8 September 2016; accepted 10 November 2016
Introduction
In the UK and most European countries, cardiovascu-
lar disease (CVD) risk increases at lower temperatures,
a typical element of the cold season.1,2 As CVD risk
during the cold season is more markedly increased in
older rather than younger adults,3 investigating
temperature-related variations in CVD risk factors in
older adults is of particular interest.
It has been hypothesised that lower outdoor tem-
peratures could exert their adverse eﬀects by increasing
the levels of well-established risk factors causally
associated with coronary heart disease (CHD),4,5 such
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as blood pressure6 and lipids.7 However, associations of
temperature with recently established causal risk
factors for CHD, such as interleukin-6,8 are not well
studied.9 Also, low outdoor temperatures may increase
the levels of other novel risk factors prospectively asso-
ciated with CVD (e.g. inﬂammatory markers, haemo-
static markers),10 although the literature supporting
this hypothesis is sparse.9,11 Higher outdoor tempera-
ture is also a proxy measure for sunlight exposure, and
hence potentially related to the level of vitamin D
which has consistently been associated with chronic
disease incidence although its causal association
remains hotly debated.12
Common limitations of previous studies investigat-
ing associations of outdoor temperature and CVD risk
factors are small sample size,13,14 the speciﬁc geograph-
ical location,11 and the investigation of clinical popula-
tions.15 Therefore, large population-based studies
which explore associations of outdoor temperature
with a comprehensive range of CVD risk factors are
required to improve statistical power and estimate
precision.
Considering the gaps in knowledge from previous
research, the aim of this study was to investigate the
strength of relationship between established and novel
biological risk factors and outdoor temperature in two
large Northern European studies of older adults.
Methods and participants
Participants from the British Regional Heart Study
(BRHS) and the Prospective Study of Pravastatin in
the Elderly at Risk (PROSPER) provided informed writ-
ten consent, which was performed in accordance with
the principles of the Declaration of Helsinki. The designs
of BRHS and PROSPER, both prospective studies of
cardiovascular disease comprising several thousand
participants, have been previously described.16
Cardiovascular risk factors measurement (outcomes)
For both BRHS and PROSPER, details of measure-
ment values and classiﬁcation methods for the cardio-
vascular risk factors were extensively described16 and
are brieﬂy reported here in the Supplementary
Material, Cardiovascular Risk Factors Measurements.
The measurements were carried out during 1997–2000,
and the factors included (a) established risk factors,
such as systolic and diastolic blood pressure (BP)
obtained sitting, and blood lipids (triglycerides, total
cholesterol, high density lipoprotein (HDL) cholesterol,
and low density lipoprotein (LDL) cholesterol); and (b)
novel risk factors, such as inﬂammatory factors
(C-reactive protein (CRP), ﬁbrinogen, interleukin
6 (IL-6)) and plasma viscosity (PV); haemostatic
markers (tissue plasminogen activator (t-PA) antigen,
ﬁbrin D-dimer, von Willebrand factor (vWF); and vita-
min D (VitD).
Temperature data
National meteorological oﬃces provided daily outdoor
mean temperatures for the 24 towns of BRHS and three
locations of PROSPER during the study period.
Deﬁnition of outdoor mean temperature on the exam-
ination day (lag 0) has been extensively described
elsewhere.16
Statistical methods
Descriptive statistics
Temperature and the unadjusted outcomes’ levels were
examined by month of measurement. Then, excepting
total cholesterol, p, HDL-cholesterol, LDL-cholesterol,
systolic BP (SBP) and diastolic BP (DBP), all other out-
comes were log-transformed for further analysis as their
distributions were positively skewed.
Associations (main effects) of temperature
with the CVD risk factors
For log-transformed outcomes, associations were
reported as the percentage change in the geometric
mean associated with a decrease of 5C in mean tem-
perature (5C being the standard deviation of daily
mean temperature for the years 1997–2000 in the
BRHS and PROSPER towns). Associations of
temperature with BP variables, HDL-cholesterol,
LDL-cholesterol, and total cholesterol, were reported
as linear coeﬃcients (absolute change) per decrease of
5C in mean temperature.
Before being considered for pooling, data from the
BRHS and PROSPER were analysed separately due to
diﬀerences in study design, inclusion criteria and meas-
urement protocols. In BRHS, multilevel linear regres-
sion models (level 1¼ individual, level 2¼ town of
examination) were used to take into account clustering
within towns.17 Associations were adjusted for estab-
lished CVD risk factors and possible confounders, such
as age, body mass index (BMI), social class, smoking,
alcohol consumption, physical activity score and time
of day (measurement variable).9 In PROSPER, linear
regression models were used to estimate the associ-
ations of temperature with the outcomes. Associations
were adjusted for the same variables as for BRHS
except for physical activity, social class, and time of
day which were not ascertained, but for sex and loca-
tion. In BRHS and PROSPER separately, the propor-
tion of variance associated with temperature from
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the fully adjusted models was estimated using partial
R-squared. We also ﬁtted an interaction between tem-
perature and age (both ﬁtted as continuous variables)
to test whether the relationship of temperature with
outcomes was particularly marked among older
participants.
Pooled analysis
Regression coeﬃcients from fully adjusted models of
BRHS and PROSPER were pooled using a random
eﬀects model, to take account of heterogeneity between
the two studies where it occurred, for each of the out-
comes separately.
Sensitivity analysis
The cumulative short-term eﬀect of temperature on the
CVD risk factors was also investigated, using the
temperature moving average of seven days which
included lag days from 0–6 prior to the examination
day (lag 0–6).
An additional adjustment of outdoor temperature
(at lag 0) with a seasonal term, such as day length or
sine and cosine terms,18 was evaluated. However, since
the variance inﬂation factor scores were between 9–13
for these seasonal terms when included with tempera-
ture, collinearity would have been induced and there-
fore the adjustment was not recommended in this case.
Alternatively, we tested an adjustment of temperature
with season ﬁtted as binary variable (winter
(December–March) vs summer (April–November)).
In BRHS, outdoor temperature was also addition-
ally adjusted for indoor temperature (not available in
PROSPER). As indoor temperature did not have any
eﬀect on the outcomes (all p> 0.05), and did not alter
the magnitude of the associations of outdoor tempera-
ture with outcomes, it was not considered further.
As lung function measurement (forced expiratory
volume in one second, or FEV1) was also available in
the BRHS, a further sensitivity analysis was carried out
adding FEV1 as covariate in models predicting CRP
levels, to take into account the possible temperature-
related variation in CRP due to poor respiratory health
in winter.
Results
Participants
The BRHS and PROSPER participants’ characteristics
are shown in Table 1. In BRHS, 4252 men out of 5516
survivors (77%) were examined during the study
period. In PROSPER, 5804 participants out of 23,770
(24%) screened individuals participated in the clinical
Table 1. The British Regional Heart Study (BRHS) and
Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)
participant characteristics during examinations (1997–2000).
BRHS men
(n¼ 4252)1
PROSPER
participants
(n¼ 5804)2
Demographic and background characteristics
Sex (male), n (%) 4252 (100) 2806 (48.0)
Age (years), mean (SD) 68.7 (5.5) 75.3 (3.3)
Social class (manual), n (%) 2166 (51.0) –
Physical health
Prevalence of stroke/
myocardial infarction, n (%)
370 (8.7) 979 (16.9)
Hypertension, n (%) 2703 (63.8) 3592 (61.9)
Diabetes, n (%) 380 (9.4) 623 (10.7)
BMI, mean (SD) 26.9 (3.7) 26.8 (4.1)
Behavioural factors
Smoking
Never, n (%) 1233 (29.1) 1969 (33.9)
Ex-smokers, n (%) 2464 (58.0) 2277 (39.2)
Smokers, n (%) 548 (12.9) 1558 (26.8)
Alcohol consumption
None, n (%) 431 (10.3) 2576 (44.4)
Occasional/light, n (%) 3 2949 (70.5) 2698 (46.5)
Moderate/heavy, n (%) 4 779 (18.6) 530 (9.1)
Unclassified, n (%) 26 (0.6) –
Physical activity (PA) score
Inactive, n (%) 471 (11.5) –
Occasional, n (%) 957 (23.4) –
Light, n (%) 767 (18.7) –
Moderate, n (%) 591 (14.4) –
Moderate vigorous, n (%) 690 (16.8) –
Vigorous, n (%) 621 (15.2) –
Biological markers, means (SD)
CRP, mg/l 3.53 (6.86) 5.94 (11.07)
IL-6, pg/ml 3.18 (2.95) 3.40 (3.08)
Fibrinogen, g/l 3.27 (0.74) 3.59 (0.74)
PV, mPa.s 1.285 (0.078) 1.296 (0.077)
t-PA, ng/ml 11.08 (4.44) 11.02 (4.04)
vWF, IU/dl 139.96 (46.19) 140.62 (45.98)
D-dimer, ng/ml 133.58 (210.74) 316.85 (189.48)
Tryglicerides, mmol/l 1.86 (1.08) 1.54 (0.74)
HDL-cholesterol, mmol/l 1.32 (0.34) 1.28 (0.36)
LDL-cholesterol, mmol/l 3.89 (0.97) 3.78 (0.83)
Total cholesterol, mmol/l 6.00 (1.08) 5.66 (0.94)
Vitamin D, ng/ml 20.01 (9.24) 16.57 (9.94)
SBP sitting, mm Hg 149 (24) 155 (22)
DBP sitting, mm Hg 85 (11) 84 (11)
BMI: body mass index; CRP: C-reactive protein; DBP: diastolic blood
pressure; HDL: high density lipoprotein; IL-6: interleukin 6; LDL: low
density lipoprotein; PV: plasma viscosity; SBP: systolic blood pressure;
SD: standard deviation; t-PA: tissue plasminogen activator; vWF: von
Willebrand factor.
1BRHS men from England and Wales: n¼ 3804 (89.5%); from Scotland:
n¼ 448 (10.5%).
2Participants from Glasgow: n¼ 2520 (43.4%); from Cork: n¼ 2184
(37.6%), and from Leiden: n¼ 1100 (19.0%).
31 and 15 units per week (one unit is approximately one drink, such as
one glass of wine).
416 units per week (one unit is approximately one drink, such as one
glass of wine).
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trial of pravastatin vs placebo. PROSPER participants
were on average about seven years older than BRHS
participants, with a higher percentage of never-
smokers, and were less likely to drink alcohol (Table 1).
Outdoor temperature of the day of examination
by month
In both studies, daily mean temperatures on the day of
examination were usually between 4–9C from
November–April and between 10–16C from May–
October (see Supplementary Material, eTable 1).
CVD risk factors descriptive statistics by month
Highest levels of the CVD risk factors analysed were
observed from November–April (see Supplementary
Material, eTables 2–5). This variation was particularly
marked for SBP, DBP, total cholesterol, CRP, IL-6,
t-PA, vWF and PV. Conversely, VitD levels were
lowest in colder months.
Associations of temperature with the CVD
risk factors
Adjusted associations of mean temperature on
day of measurement with the CVD risk factors
are shown in Table 2 for each study separately, and
pooled.
Pooled estimates showed that with a 5C lower mean
temperature, total cholesterol was 0.04mmol/l (95%
conﬁdence interval (CI) 0.02–0.07) higher, LDL choles-
terol was 0.02mmol/l (95% CI 0.01–0.05) higher, and
SBP was 1.12mm Hg (95% CI 0.60–1.64) higher.
Among novel CVD risk factors, CRP was 3.3% (95%
CI 1.0–5.6%) higher, IL-6 was 2.7% (95% CI
1.1–4.3%) higher, t-PA was 1.9% (95% CI 1.0–2.9%)
higher, ﬁbrinogen was 0.7% (95% CI 0.2–1.3%) higher,
and plasma viscosity was 0.4% (95% CI 0.3–0.5%)
higher. There was no evidence of heterogeneity between
studies (p-values> 0.05).
With a 5C lower mean temperature, VitD was
11.2% (95% CI 1.0–20.4%) lower. In this case,
there was evidence of heterogeneity between studies
(I2¼ 97.3%; p-value< 0.001), though the eﬀect was
in the same direction and statistically signiﬁcant for
both studies.
Associations of temperature with DBP, vWF and
D-dimer, triglycerides, and HDL-cholesterol were not
statistically signiﬁcant. Results for HDL-cholesterol
suggested heterogeneity (I2¼ 90.6%; p-value¼ 0.001)
with association of a decrease in temperature signiﬁcant
for the PROSPER study only.
Proportion of variance in risk factors explained
by temperature
The highest proportion of variance was observed when
the outcome analysed was VitD (5.1% and 5.6% in the
BRHS and PROSPER fully adjusted models respect-
ively). In each of the models, and other outcomes ana-
lysed, the proportion of variance associated with mean
temperature was less than 1% (Supplementary
Material, eTable 6).
Interactions between temperature and age
Interaction eﬀects of temperature with age on the out-
comes levels were mainly not signiﬁcant (data not
shown). However, interactions were found in
PROSPER alone for VitD and HDL-cholesterol.
A 5C decrease in mean temperature was associated
with an additional decrease of –0.8% per year of age
(95% CI –1.4– –0.3%) for Vitamin D, and
þ0.003mmol/l per year of age (95% CI 0–0.006)
for HDL-cholesterol. No interactions were found in
BRHS.
Sensitivity analysis
Cumulative short-term associations of temperature up
to one week (lag 0–6) prior to the examination day with
the CVD risk factors levels were observed (not shown).
As the magnitude of the associations was very similar
to associations using temperature at lag 0 (primary ana-
lysis), only associations at lag 0 were presented.
An additional adjustment for season ﬁtted as binary
variable (winter vs summer) barely changed the magni-
tude of the associations of outdoor temperature (results
were not shown).
In BRHS, an additional adjustment for lung func-
tion (FEV1) did not substantially change the eﬀect of
CRP: the percentage increase in CRP due to a decrease
in temperature was 4.1% (0.7–7.3%) and 4.6%
(1.4–7.8%) for models without and with lung function.
Discussion
To our knowledge, the pooled analysis of the BRHS
and PROSPER is the largest investigation of the rela-
tionships between outdoor temperature and an exten-
sive range of CVD risk factors, both established and
novel in older European people. The CVD risk factors
investigated here were selected for two reasons: ﬁrst,
there was published evidence of seasonal variation,
with higher levels observed in the cold season
(November–April); second, there was published
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evidence of independent association with CVD events
in meta-analyses of prospective population-based
studies.19–22
Overall findings
Lower outdoor temperature, measured on the day of
clinical examination, was associated with higher levels
of most CVD risk factors analysed. Conversely, lower
outdoor temperature was associated with a lower VitD.
The direction and magnitude of these associations were
similar in comparison with other studies,6,7,11 and per-
sisted after adjustment for classic risk factors such as
age, BMI, smoking, alcohol consumption, and physical
activity. The ﬁndings were similar when using the out-
door temperature moving average of seven days, which
included lag days from 0–6 prior to the examination day
(lag 0–6). In fully adjusted models, the proportion of
variance in risk factors explained by temperature was
much smaller than other risk factors, being around 1%
of the total variance (except for VitD, where variance
explained was approximately 5%). There was no
Table 2. The change in the levels of cardiovascular disease (CVD) risk factors for a single standard deviation (5C) decrease in
outdoor mean temperature in the British Regional Heart Study (BRHS) and Prospective Study of Pravastatin in the Elderly at Risk
(PROSPER) participants, during examinations (1997–2000).
POOLED (BRHSþ PROSPER)c
BRHSa PROSPERb
Test of
heterogeneity
Percentage
change (95% CI) p-Value
Percentage
change (95% CI) p-Value
Percentage
change (95% CI) I2 (%) p-Value
CRP, mg/l 4.1 (0.7–7.3) 0.017 2.4 (–0.8–5.7) 0.075 3.3 (1.0–5.6) 0.0 0.468
IL-6, pg/ml 1.8 (–1.3–4.8) 0.246 3.0 (1.1–4.9) 0.001 2.7 (1.1–4.3) 0.0 0.525
Fibrinogen, g/l 0.5 (–0.5–1.6) 0.286 0.8 (0.2–1.4) 0.007 0.7 (0.2–1.3) 0.0 0.677
t-PA, ng/ml 2.5 (0.6–4.4) 0.010 1.7 (0.6–2.8) <0.001 1.9 (1.0–2.9) 40.6 0.461
PV, mPa.s 0.4 (0.2–0.6) <0.001 0.4 (0.3–0.6) <0.001 0.4 (0.3–0.5) 0.0 1.000
vWF, IU/dl –1.0 (–2.6–0.7) 0.268 1.0 (0.0–2.0) 0.029 0.1 (–1.7–2.1) 74.0 0.050
D-dimer, ng/ml 1.6 (–1.5–4.6) 0.292 –0.6 (–2.1–0.9) 0.482 0.1 (–1.9–2.2) 0.0 0.516
Vitamin D, ng/ml –6.1 (–9.1– –3.2) <0.001 –16.0 (–17.5– –14.5) <0.001 –11.2 (–20.4– –1.0) 97.3 <0.001
Triglycerides,
mmol/l
1.5 (–0.7–3.6) 0.175 –0.1 (–1.3–1.1) 0.442 0.4 (–1.0–1.9) 39.3 0.199
Absolute change
(95% CI) p-Value
Absolute
change (95% CI) p-Value
Absolute
change (95% CI) I2 (%) p-Value
HDL-cholesterol,
mmol/l
0.00 (–0.01–0.02) 0.844 0.03 (0.02–0.04) <0.001 0.02 (–0.01–0.05) 90.6 0.001
LDL-cholesterol,
mmol/l
0.05 (0.00–0.09) 0.039 0.02 (0.00–0.05) 0.038 0.03 (0.01–0.05) 0.0 0.346
Total cholesterol,
mmol/l
0.06 (0.01–0.11) 0.015 0.04 (0.01–0.06) 0.004 0.04 (0.02–0.07) 0.0 0.464
SBP sitting,
mm Hg
1.22 (0.29–2.16) 0.010 1.08 (0.45–1.71) <0.001 1.12 (0.60–1.64) 0.0 0.796
DBP sitting,
mm Hg
0.47 (0.04–0.90) 0.032 0.13 (–0.20–0.46) 0.270 0.27 (–0.06–0.60) 34.5 0.217
BMI: body mass index; CI: confidence interval; CRP: C-reactive protein; DBP: diastolic blood pressure; HDL: high density lipoprotein; IL-6: interleukin
6; LDL: low density lipoprotein; PV: plasma viscosity; SBP: systolic blood pressure; t-PA: tissue plasminogen activator; vWF: von Willebrand factor.
aMultilevel linear regression models (level 1¼ individual, level 2¼ town of examination) were used. The models were adjusted for age, social class, BMI,
smoking, alcohol consumption, physical activity, and time of measurement. Complete case analysis (n¼ 3832)
bLinear regression models were used. The models were adjusted for town, age, BMI, smoking, alcohol consumption, and sex. Complete case analysis
(n¼ 5804)
cResults from the two studies were pooled using a random effects model. The command metan with the option random available in Stata/SE 14. The
percentage of variation across studies that is due to heterogeneity was reported using the I2 statistic.
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consistent evidence of an interaction of temperature with
age on the wide range of CVD risk factors analysed.
These ﬁndings would be consistent with the sugges-
tions from previous studies that, in addition to estab-
lished risk factors such as cholesterol7 and BP,6
circulating inﬂammatory markers,9 and VitD23
showed strong associations with outdoor temperature
and may contribute to increased incidence of CVD in
winter.1 The association of temperature with SBP,
LDL-cholesterol and IL-6 levels may be particularly
relevant, as previous trials and Mendelian randomiza-
tion (MR) studies support their causal role in CHD
risk.4,5,24
Established CVD risk factors
In this study lower outdoor temperatures were signiﬁ-
cantly associated with higher levels of SBP consistently
with previous ﬁndings.25 The association with DBP was
weaker and non-signiﬁcant. Seasonal variation in SBP
was previously shown to be greater in older than in
younger subjects (while DBP was similar), and highly
signiﬁcantly related to outdoor temperature.26
We found decrease in temperature was associated
with increased total cholesterol and LDL-cholesterol,
as previously reported.27 In our study, a decrease of
about 10C in temperatures would be associated with
an increase of 0.06mmol/l in LDL-cholesterol.
According to previous studies, this absolute increase
in LDL-cholesterol leads to an increase of approxi-
mately 1% in CVD mortality risk.4 The importance
of HDL-cholesterol as a marker of CHD risk has
been emphasised through its inclusion in the
Framingham Risk Score.28 When pooling results from
the two studies, we found no clear association between
temperature and HDL-cholesterol although a positive
association was seen in PROSPER. Lastly, associations
of temperature with triglycerides were not signiﬁcant as
observed in previous studies.7
Novel CVD risk factors
A decrease in temperature was associated with
increased circulating levels of markers of inﬂammation,
such as IL-6, CRP, ﬁbrinogen and plasma viscosity.
The inﬂammatory hypothesis of CVD is currently
being formally tested in randomized controlled trials
(RCTs).24 To date, MR studies for IL-6 suggested a
causal role in CHD, in contrast to null associations in
MR studies for CRP and ﬁbrinogen.8 Therefore, the
ﬁndings on IL-6 are particularly important: in this
study a decrease of about 10C in temperatures (diﬀer-
ence between the coldest and warmest month, January–
August) would be associated with an increase of
0.06 pg/ml in IL-6 levels. According to previous IL-6
observational data this absolute diﬀerence was asso-
ciated to an increase of 4.5% in CVD deaths.29 This
broad estimation is in line with previous studies which
took place in the same years (1998–2007) and attributed
to temperatures 7% of the winter mortality in England
and Wales.30
It is also possible that an acute (or short-term) eﬀect
of outdoor temperature may be more marked on rap-
idly responding CVD risk factors, such as CRP.31 The
CRP behaviour may explain why it provides closer
associations and better predictions of CVD events in
the short-term than other markers of inﬂammation.
The associations of temperature with other speciﬁc
markers of inﬂammation we studied, such as ﬁbrinogen
and plasma viscosity, were smaller in comparison with
CRP, as previously reported.15
Findings for PV and t-PA are similar in comparison
with previous studies which observed higher levels of
these factors in winter,9 although the eﬀect of tempera-
ture was not speciﬁcally tested. To our knowledge these
associations with temperature are novel, and have not
been previously published. On the other hand, the asso-
ciation of temperature with vWF and ﬁbrin D-dimer
was not signiﬁcant. The seasonal variation in tempera-
ture did not show a good agreement with variations
observed in vWF and D-dimer: vWF’s seasonal peak
was previously observed in early spring (between
March–May)9 when outdoor temperature already
started its annual average increase from February;
D-dimer seemed to have an unusual seasonal variation,
with peaks in February/March and August/
September.32
VitD
Findings for VitD showed strong associations with
temperature in pooled analysis, though this varied
between the studies. However, for VitD speciﬁcally,
temperature is likely to be a proxy of exposure to sun-
light, which is the real determinant. In our study a
decrease of about 10C in temperatures would be asso-
ciated with a decrease of approximately 4 ng/ml
(¼10 nmol/l) in VitD levels. According to previous
observational studies, this absolute decrease in VitD
is associated with an increase of approximately 4% in
CVD deaths and events12 although any causal role
remains contentious.
Strengths and limitations
By pooling PROSPER and BRHS we substantially
improved statistical power and precision in comparison
with ﬁndings reported in other studies of older adults.
The participants lived mostly in the UK but also in
Ireland and the Netherlands. The PROSPER study
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included both women and men. Moreover, novel CVD
risk factors measurements in both studies were per-
formed over the same time period, in the same
Glasgow University laboratories using the same
assays. However, the two study designs are diﬀerent
and this may partially explain the heterogeneity of
the ﬁndings for HDL cholesterol, as well as the inter-
actions of temperature with age; the PROSPER par-
ticipants in comparison with the BRHS participants
were about seven years older on average, with a
higher percentage of never-smokers, and less likely
to drink alcohol. They were also at elevated CVD
risk and around half had prevalent CVD. Due to
the nature of our data and risk of collinearity between
temperature and other seasonal terms, it was not pos-
sible to distinguish between temperature-related eﬀects
and eﬀects due to other factors which are known to
vary by season: for example, in winter higher preva-
lence of inﬂuenza or other respiratory viruses or dis-
eases, such as rheumatic disorders, may be relevant to
the CRP seasonal variation. Despite this limitation,
we took into account of season as binary variable
(winter vs summer), and alternatively ﬁtting respira-
tory health in sensitivity analysis: an additional adjust-
ment for lung function was performed and speciﬁcally
when using CRP as outcome. The results still showed
that lower outdoor temperatures were signiﬁcantly
associated with an increase in the outcome levels.
Moreover, although indoor temperature was not avail-
able in the PROSPER, we added this variable in the
BRHS models and we showed the eﬀect of outdoor
temperatures was not confounded by indoor
temperatures.
Implications
Our study provides robust evidence that outdoor
temperature is associated with variations in the
major CVD risk factors in older adults. This study
increased generalisability of existing evidence from
northern European older populations and is consist-
ent with the hypothesis that inﬂammation markers,
on top of BP and LDL-cholesterol changes, could
play a key role in intermediate processes leading to
the cold-related CVD mortality. Also, there was no
consistent evidence of an interaction of temperature
with age (participants in the two studies ranged from
60–82 years old) on the wide range of CVD risk fac-
tors analysed; this ﬁnding suggested that the eﬀect of
low temperature on CVD risk may apply to the
full age range of older adults. Public health
approaches to protect elderly populations against
low temperatures could help in reducing levels of sev-
eral CVD risk factors, and thus CVD risk itself,
in winter.
Conclusions
Variations of outdoor temperature in the short-term
were associated with variations in the majority of
CVD risk factors analysed. Associations were strongest
with inﬂammatory factors (particularly CRP, and its
major cytokine driver, IL-6) and VitD, followed by
associations with SBP, and cholesterol variables.
Better protection against low temperatures could help
in reducing the levels of several CVD risk factors.
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